Use este identificador para citar ou linkar para este item:
http://hdl.handle.net/1843/56492| Tipo: | Artigo de Periódico |
| Título: | Reduced Activated T Lymphocytes (CD4+CD25+) and Plasma Levels of Cytokines in Parkinson’s Disease |
| Autor(es): | Natalia Pessoa Rocha Frankcinéia Assis Paula Luciana Scalzo Érica Leandro Marciano Vieira Izabela Guimarães Barbosa Mariana Soares de Souza Paulo Pereira Christo Helton José Reis Antonio Lucio Teixeira Junior |
| Resumo: | Abstract Parkinson’s disease (PD) is the second most com mon neurodegenerative disease. The cause of neurodegeneration in PD is not completely understood, and evidence has shown that inflammatory/immune changes may be involved in PD pathophysiology. Herein, we aimed to determine the profile of the peripheral immune system in patients with PD in comparison with controls. Forty patients with PD and 25 age- and gender-matched controls were enrolled in this study. From these, 23 PD patients and 21 controls were included in the immunophenotyping analyses. Peripheral blood was drawn on the same day of the clinical assessment and submitted to plasma separation for enzyme-linked immunosorbent assay or cytometric bead array. Immunophenotyping analyses of the peripheral blood were performed by flow cytometry. We found that patients with PD presented peripheral immune changes evidenced by decreased percentage of T lymphocytes (CD3+ cells), especially activated T lymphocytes (CD4+CD25+ cells), when compared with controls. In line with these results, we also found decreased plasma levels of the cytokines IL-4, IL-6, IL-10, TNF, IFN-γ, and IL-17A in the PD group. In vitro experiments demonstrated that the produc tion of cytokines by peripheral blood mononuclear cells harvested from healthy young donors was reduced after exposure to the anti-parkinsonian drugs levodopa and pramipexole. Our data corroborate the hypothesis that immunological mechanisms are involved in PD. It is not clear whether the differences that we have found are due to adaptive mechanisms or to changes associated with PD, including pharmacological treatment, or even directly related to the disease pathophysi ology. Future studies are needed in this regard. |
| Assunto: | Doença de Parkinson Sistema Imunitário Imunofenotipagem Leucócitos Citocinas |
| Idioma: | eng |
| País: | Brasil |
| Editor: | Universidade Federal de Minas Gerais |
| Sigla da Instituição: | UFMG |
| Departamento: | ICB - DEPARTAMENTO DE FARMACOLOGIA ICB - DEPARTAMENTO DE MORFOLOGIA MED - DEPARTAMENTO DE CLÍNICA MÉDICA |
| Tipo de Acesso: | Acesso Restrito |
| Identificador DOI: | https://doi.org/10.1007/s12035-017-0404-y |
| URI: | http://hdl.handle.net/1843/56492 |
| Data do documento: | 7-Fev-2017 |
| metadata.dc.url.externa: | https://link.springer.com/article/10.1007/s12035-017-0404-y |
| metadata.dc.relation.ispartof: | Molecular Neurobiology |
| Aparece nas coleções: | Artigo de Periódico |
Arquivos associados a este item:
Não existem arquivos associados a este item.
Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.